Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor - PubMed
Human osteosarcoma (U-2 OS) cells express both insulin-like growth factor-I (IGF-I) receptors and insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptors and synthesize IGF-II: autocrine growth stimulation by IGF-II via the IGF-I receptor
K Raile et al. J Cell Physiol. 1994 Jun.
Abstract
Recently, insulin-like growth factor-I and -II (IGF-I and -II) have been implicated in the growth promotion of tumors in vivo and tumor cells in vitro. We have studied the human osteosarcoma cell line U-2 OS in order 1) to gain more insight into the growth promoting actions of the IGFs and 2) to establish an in vitro tissue culture model of IGF action in human tumor cells. Specific binding of 125I-IGF-I and 125I-IGF-II to IGF-I receptors and IGF-II/mannose-6-phosphate (M6P) receptors on U-2 OS cells was demonstrated in competitive binding experiments and in affinity crosslinking experiments. Western blotting of cell extracts confirmed the expression of the IGF-II/M6P receptor. In addition, in Northern blotting experiments using total RNA from U-2 OS cells IGF-I receptor RNA of 11 kb and IGF-II/M6P receptor RNA of approximately 9 kb were detected. Solution hybridization experiments confirmed the presence of IGF-I receptor and IGF-II/M6P receptor RNA. In a subset of experiments DNA synthesis was measured as 3H-thymidine uptake into cellular DNA of U-2 OS cells. Normal rat serum stimulated DNA synthesis maximally. IGF-I-deficient serum from hypophysectomized rats as well as IGF-I or IGF-II without serum were approximately twofold and tenfold, respectively, less potent than serum in stimulating 3H-thymidine uptake. The concentrations of IGF-I and IGF-II needed for half maximal stimulation of DNA synthesis corresponded well with the respective concentrations required for half maximal inhibition of 125I-IGF-I binding to U-2 OS cells. The anti-IGF-I receptor antibody alpha IR3 blocked the IGF-I and IGF-II stimulated increase of 3H-thymidine uptake. In addition, basal DNA synthesis was partially inhibited by the anti-IGF-I receptor antibody. These data suggest that U-2 OS cells synthesize and secrete IGF-like peptides. Northern blotting experiments confirmed that U-2 OS cells express an IGF-II RNA species of 5.3 kb but no IGF-I transcripts. In a series of RNase protection assays, protected RNA fragments were detected with an IGF-II riboprobe. Also, cell-conditioned medium from U-2 OS cells contained 1-2 ng/ml IGF-II immunoreactivity as measured in an IGF-binding protein blocked IGF-II radioimmunoassay.
In conclusion: 1) U-2 OS cells express IGF-I and IGF-II/M6P receptors. 2) U-2 OS tumor cells respond to the addition of exogenous IGF-I and IGF-II with an increase of DNA synthesis.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Yang Y, Hoeflich A, Kessler U, Barenton B, Blum W, Schwarz HP, Kiess W. Yang Y, et al. Regul Pept. 1993 Oct 20;48(1-2):41-53. doi: 10.1016/0167-0115(93)90334-5. Regul Pept. 1993. PMID: 8265816
-
Hoeflich A, Yang Y, Kessler U, Heinz-Erian P, Kolb H, Kiess W. Hoeflich A, et al. Mol Cell Endocrinol. 1994 May;101(1-2):141-50. doi: 10.1016/0303-7207(94)90228-3. Mol Cell Endocrinol. 1994. PMID: 9397946
-
Takigawa M, Okawa T, Pan H, Aoki C, Takahashi K, Zue J, Suzuki F, Kinoshita A. Takigawa M, et al. Endocrinology. 1997 Oct;138(10):4390-400. doi: 10.1210/endo.138.10.5265. Endocrinology. 1997. PMID: 9322955
-
Insulin-like growth factor II: complexity of biosynthesis and receptor binding.
Gammeltoft S, Christiansen J, Nielsen FC, Verland S. Gammeltoft S, et al. Adv Exp Med Biol. 1991;293:31-44. doi: 10.1007/978-1-4684-5949-4_4. Adv Exp Med Biol. 1991. PMID: 1722620 Review.
-
Kiess W, Yang Y, Kessler U, Hoeflich A. Kiess W, et al. Horm Res. 1994;41 Suppl 2:66-73. doi: 10.1159/000183963. Horm Res. 1994. PMID: 8088706 Review.
Cited by
-
Targeting IL-11R/EZH2 signaling axis as a therapeutic strategy for osteosarcoma lung metastases.
Devarajan E, Davis RE, Beird HC, Wang WL, Jensen VB, Jayakumar A, Leung CH, Lin HY, Wu CC, Ihezie SA, Tsai JW, Futreal PA, Lewis VO. Devarajan E, et al. Discov Oncol. 2024 Jun 18;15(1):232. doi: 10.1007/s12672-024-01056-3. Discov Oncol. 2024. PMID: 38886296 Free PMC article.
-
Gene Editing Targeting the DUX4 Polyadenylation Signal: A Therapy for FSHD?
Joubert R, Mariot V, Charpentier M, Concordet JP, Dumonceaux J. Joubert R, et al. J Pers Med. 2020 Dec 23;11(1):7. doi: 10.3390/jpm11010007. J Pers Med. 2020. PMID: 33374516 Free PMC article.
-
Chiu YJ, Hour MJ, Jin YA, Lu CC, Tsai FJ, Chen TL, Ma H, Juan YN, Yang JS. Chiu YJ, et al. Int J Oncol. 2018 May;52(5):1465-1478. doi: 10.3892/ijo.2018.4325. Epub 2018 Mar 16. Int J Oncol. 2018. PMID: 29568964 Free PMC article.
-
Silencing SATB1 inhibits proliferation of human osteosarcoma U2OS cells.
Zhang H, Qu S, Li S, Wang Y, Li Y, Wang Y, Wang Z, Li R. Zhang H, et al. Mol Cell Biochem. 2013 Jun;378(1-2):39-45. doi: 10.1007/s11010-013-1591-0. Epub 2013 Mar 21. Mol Cell Biochem. 2013. PMID: 23516037
-
Sikaria S, Heim-Hall J, Diaz EH, Williams R, Sankhala K, Laabs B, Mita M. Sikaria S, et al. Target Oncol. 2014 Mar;9(1):73-9. doi: 10.1007/s11523-013-0267-8. Epub 2013 Feb 21. Target Oncol. 2014. PMID: 23430345 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical